Literature DB >> 26954998

Homogeneous time-resolved G protein-coupled receptor-ligand binding assay based on fluorescence cross-correlation spectroscopy.

Thomas Antoine1, David Ott1, Katharina Ebell1, Kerrin Hansen1, Luc Henry2, Frank Becker1, Stefan Hannus3.   

Abstract

G protein-coupled receptors (GPCRs) mediate many important physiological functions and are considered as one of the most successful therapeutic target classes for a wide spectrum of diseases. Drug discovery projects generally benefit from a broad range of experimental approaches for screening compound libraries and for the characterization of binding modes of drug candidates. Owing to the difficulties in solubilizing and purifying GPCRs, assay formats have been so far mainly limited to cell-based functional assays and radioligand binding assays. In this study, we used fluorescence cross-correlation spectroscopy (FCCS) to analyze the interaction of detergent-solubilized receptors to various types of GPCR ligands: endogenous peptides, small molecules, and a large surrogate antagonist represented by a blocking monoclonal antibody. Our work demonstrates the suitability of the homogeneous and time-resolved FCCS assay format for a robust, high-throughput determination of receptor-ligand binding affinities and kinetic rate constants for various therapeutically relevant GPCRs.
Copyright © 2016 The Authors. Published by Elsevier Inc. All rights reserved.

Keywords:  Affinity determination; Binding kinetics; Fluorescence correlation spectroscopy; Fluorescence cross-correlation spectroscopy; GPCR; Homogeneous time-resolved binding assay

Mesh:

Substances:

Year:  2016        PMID: 26954998     DOI: 10.1016/j.ab.2016.02.017

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  6 in total

1.  High-Affinity Binding of Chemokine Analogs that Display Ligand Bias at the HIV-1 Coreceptor CCR5.

Authors:  Carlos A Rico; Yamina A Berchiche; Mizuho Horioka; Jennifer C Peeler; Emily Lorenzen; He Tian; Manija A Kazmi; Alexandre Fürstenberg; Hubert Gaertner; Oliver Hartley; Thomas P Sakmar; Thomas Huber
Journal:  Biophys J       Date:  2019-08-02       Impact factor: 4.033

2.  XPO1 target occupancy measurements confirm the selinexor recommended phase 2 dose.

Authors:  Marsha L Crochiere; Stefan Hannus; Kerrin Hansen; Frank Becker; Erkan Baloglu; Margaret Lee; Michael Kauffman; Sharon Shacham; Yosef Landesman
Journal:  Oncotarget       Date:  2017-11-30

3.  Fluorescence Labeling of Neurotensin(8-13) via Arginine Residues Gives Molecular Tools with High Receptor Affinity.

Authors:  Max Keller; Shahani A Mahuroof; Vivyanne Hong Yee; Jessica Carpenter; Lisa Schindler; Timo Littmann; Andrea Pegoli; Harald Hübner; Günther Bernhardt; Peter Gmeiner; Nicholas D Holliday
Journal:  ACS Med Chem Lett       Date:  2019-11-19       Impact factor: 4.345

4.  Considerations for improved performance of competition association assays analysed with the Motulsky-Mahan's "kinetics of competitive binding" model.

Authors:  Victoria Georgi; Alexey Dubrovskiy; Stephan Steigele; Amaury E Fernández-Montalván
Journal:  Br J Pharmacol       Date:  2019-12-26       Impact factor: 8.739

5.  Isolated metastasis of an EGFR-L858R-mutated NSCLC of the meninges: the potential impact of CXCL12/CXCR4 axis in EGFRmut NSCLC in diagnosis, follow-up and treatment.

Authors:  Florian Lüke; Raquel Blazquez; Rezan Fahrioglu Yamaci; Xin Lu; Benedikt Pregler; Stefan Hannus; Karin Menhart; Dirk Hellwig; Hans-Jürgen Wester; Saskia Kropf; Daniel Heudobler; Jirka Grosse; Jutta Moosbauer; Markus Hutterer; Peter Hau; Markus J Riemenschneider; Michaela Bayerlová; Annalen Bleckmann; Bernhard Polzer; Tim Beißbarth; Christoph A Klein; Tobias Pukrop
Journal:  Oncotarget       Date:  2018-04-10

6.  A Systematic Test of Receptor Binding Kinetics for Ligands in Tumor Necrosis Factor Superfamily by Computational Simulations.

Authors:  Zhaoqian Su; Yinghao Wu
Journal:  Int J Mol Sci       Date:  2020-03-05       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.